Phase 2
N=18
Ga-DOTATATE PET for Phosphaturic Mesenchymal Tumors in Patients With Tumor Induced Osteomalacia
Osteomalacia
Bottom Line
View on ClinicalTrials.gov: NCT03736564 ↗Enrolled (actual)
18
Serious AEs
0.0%
Results posted
Apr 2025
Primary outcome: Primary: Number of Participants With Positive Localization of Phosphaturic Mesenchymal Tumors (PMTs) — 15 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- 68Ga-DOTATATE PET/CT (Combination_product)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Mayo Clinic
- Primary completion
- Oct 2023
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Positive Localization of Phosphaturic Mesenchymal Tumors (PMTs) |
15 | — |
Summary
The researchers are trying to evaluate a newer imaging technique (Ga-DOTATATE PET/CT) to see if it is more sensitive to localize the source of the hormone, which has caused the low phosphate levels.
Eligibility Criteria
Inclusion Criteria
- Adults (18 years of age or older) seen at Mayo Clinic, Rochester for FGF23 mediated osteomalacia between 1/1/2000 and 1/30/2018 who provide informed consent to participate in the study.
Exclusion Criteria
- Pregnant
- Prisoners
- Subjects diagnosed with heritable hypophosphatemic rickets/osteomalacia
- Subjects who do not consent for the study or withdraw consent during the duration of the study.
- Subjects in whom tumor localization and successful resection has already occurred.
Data sourced from ClinicalTrials.gov (NCT03736564). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.